BioSpace News Archive

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage,

Global PARP Inhibitor Biomarkers Market is valued at US$ 897.8 Mn in 2023, and it is expected to reach US$ 1,751.6 Mn by 2031, with a CAGR of 8.8% during the forecast period of 2024-2031.

Sedana Medical AB announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States.

Crossject, a specialty pharmaceuticals company developing products for emergency situations harnessing its proprietary needle-free auto-injectors technology platform ZENEO®, reports its audited financial results for the year ending December 31, 2023.

ONWARD Medical N.V., a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury, announces its Full Year 2023 Financial and Operating Results.

PRISM BioLab, Co. Ltd. announced that it has entered into a target-exclusive research and licensing agreement with ONO PHARMACEUTICAL CO., LTD.

Indivior PLC announced its financial results for the period ending March 31, 2024.

AstraZeneca had a very strong start in 2024 with substantial Total Revenue growth of 19% in the first quarter.

deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification for sepsis and other acute infections, announces the unveiling of its UllCORE diagnostic system, currently in development, with its first application in early sepsis detection.

Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Pediatric Disease Designation as well as Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease.